menu
    • menu
    [{"orgOrder":0,"company":"Abalos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"ABX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Abalos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abalos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abalos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abalos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"ABX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Abalos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abalos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abalos Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Abalos Therapeutics

    Menu

    Abalos Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Abalos Therapeutics

                            Germany arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Abalos Therapeutics

                            Germany arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABX-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, ...

                            Details : ABX-001 is a Microorganism drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            November 17, 2025

                            Lead Product(s) : ABX-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Abalos Therapeutics

                            Germany arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Abalos Therapeutics

                            Germany arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABX-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abalos Therapeutics Doses First Patient in Phase 1 Study of ABX-001 for Solid Tumors

                            Details : ABX-001, a microorganism-based therapy, shows promise in treating refractory/relapsed solid tumors.

                            Product Name : ABX-001

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            October 23, 2025

                            Lead Product(s) : ABX-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth